top of page

A deep-dive discussion on obesity drug development with Zealand Pharma's CEO Adam Steensberg

  • Oct 10, 2024
  • 1 min read

He highlights Zealand’s three different approaches to obesity: glucagon/GLP-1, GLP-1/GLP-2, and an amylin analog. Plus, he shares his thoughts on tolerability, compliance, the development of oral GLP’s, business development, and more.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

10x_Genomics_logo.svg.png

10x Genomics delivers powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology to advance human health. Cited in more than 10,000 research papers, our innovative single cell, spatial, and in situ technologies enable discoveries across oncology, immunology, neuroscience, and more.

 

Our talented, dedicated science professionals have a distinguished record of creating innovative instruments, reagents, and software that analyze biological systems at a resolution that matches the complexity of biology.

bottom of page